Overview
Quick answer
If you searched fatty liver after a high ALT, or after an ultrasound mentioned steatosis, the first job is to separate three different questions. Blood can show whether liver cells are leaking enzymes right now. Ultrasound is the Australian first-line test for fat in the liver. A calculated score called FIB-4 then estimates the chance of advanced scar, not the amount of fat.
Australian colleges still write MAFLD, metabolic dysfunction-associated fatty liver disease. Australian Prescriber (O'Halloran, Adams, Deed and Lubel, 7 April 2026) says it affects 1 in 3 Australian adults, and more than half of people with type 2 diabetes, obesity, or two or more metabolic risk factors. The 2023 international societies renamed the older NAFLD label to MASLD. The two names overlap for most people. They are not identical definitions, and a webpage cannot relabel your report.
Abnormal liver enzymes may prompt the question. They are neither sensitive nor specific for MAFLD, and the condition can sit behind a completely normal ALT. The page people join from is not "how to reverse fatty liver." It is what the printed numbers can show, what they cannot, and which extra test is actually doing a job.
Overview
Key takeaways
Fatty liver is a description of fat in hepatocytes. Australian primary-care documents diagnose MAFLD when that fat is shown on imaging, a biomarker, or histology, plus metabolic risk. Blood enzymes alone do not make the diagnosis.
Australian Prescriber and the GESA / RACGP consensus still say MAFLD. The 2023 AASLD, EASL and ALEH Delphi says MASLD. GESA kept MAFLD because that definition allows a second cause, including alcohol, to sit beside the metabolic one.
Liver ultrasound is the recommended first-line test for hepatic steatosis in Australian primary care. Australian Prescriber cites 82% sensitivity and 80% specificity for fat in at least 5% of hepatocytes.
ALT and AST measure current cell leak, not stored fat. In the 2012 AusDiab analysis (Farrell et al., 2022), 37% of 4,747 adults met a Fatty Liver Index definition of MAFLD, and only 22% of that group had a raised ALT.
AusDiab and the Victorian CrossRoads II study both used the Fatty Liver Index, not ultrasound. Treat 37% and the CrossRoads age- and sex-standardised 35.7% as biomarker estimates, not imaged prevalence.
FIB-4 uses age, AST, ALT and platelet count to help rule out advanced fibrosis after MAFLD is on the table. GESA uses below 1.3 as low risk in adults 35 to 65. It is not a fat test. Hemexa does not calculate it.
Cardiovascular disease is the most common cause of death among people with MAFLD. A lipid and glucose pair still has a job after the liver question is asked.
Medicare can fund a standard liver panel under item 66512 when a GP has a clinical indication. Ultrasound and FIB-4 are separate requests. No medicine is TGA-approved specifically for MAFLD in Australia.
The names
Why the names keep changing
The same person can leave a consult with fatty liver, NAFLD, MAFLD, or MASLD on the letter. Those are not four diseases. They are four labels from a decade of renaming, and Australian colleges have not all moved on the same day.
Fatty liver is the search, and the ultrasound word is steatosis
Steatosis means fat inside hepatocytes. People type fatty liver. A report may say increased hepatic echogenicity. The biology is the same sentence: too much fat is stored in liver cells. That sentence is not yet a cause, a stage, or a prognosis.
NAFLD was a diagnosis by exclusion
Non-alcoholic fatty liver disease meant fat without another named cause, especially without "too much" alcohol. The 2023 Delphi (Rinella et al., Journal of Hepatology) dropped that name because it defined people by what they were not, and because "fatty" and "non-alcoholic" were judged stigmatising by a majority of the panel.
MASLD is the 2023 international rename
Metabolic dysfunction-associated steatotic liver disease needs hepatic steatosis plus at least one of five cardiometabolic risk factors. MASH is the inflamed form, formerly NASH. MetALD sits beside it for people who also drink in a defined higher band. That is the AASLD, EASL and ALEH vocabulary.
Australian colleges still write MAFLD
The GESA 2024 consensus, the Adams et al. 2025 MJA summary, and Australian Prescriber in April 2026 use metabolic dysfunction-associated fatty liver disease. GESA says most people with NAFLD also meet MAFLD, and that MAFLD can coexist with another cause, including harmful alcohol. MASLD, as GESA reads it, asks you to exclude excess alcohol first. That is why this page uses MAFLD when it cites those Australian documents, and MASLD when it cites the 2023 societies.
If your letter says NAFLD, your GP is not behind the times in a way that changes the next blood test. The useful move is to match the printed enzymes, the imaging, and the fibrosis score to the job each one can do.
Symptoms
What people feel
Most people with MAFLD feel nothing. Australian Prescriber is blunt: the condition is under-recognised because there is little public or clinician awareness, and because enzymes can be normal. People land here after a flagged ALT, an ultrasound done for something else, or a search after a type 2 diabetes or cholesterol result.
There is no specific fatty-liver symptom
Tiredness, a dull right-upper-quadrant ache, or "I just do not feel right" are common search terms. None of them names fat in the liver. Advanced disease can still be quiet until cirrhosis complications appear. Blood and imaging are filters. They are not a symptom score.
The prompt is usually a result, not a feeling
GESA and Australian Prescriber start from risk: obesity, type 2 diabetes, or two or more metabolic factors. A raised ALT is a reason to think of MAFLD. It is not required, and it is not enough.
Alcohol is a second question, not a moral one
Australian Prescriber cites alcohol-related fatty liver in 90% of people who drink more than 40 g a day (four standard drinks) over a sustained period, with 8 to 20% of that group later developing cirrhosis. NHMRC guidance for healthy adults is no more than 10 standard drinks a week and no more than 4 in one day. A metabolic picture and an alcohol history can sit in the same person. That is one reason GESA preferred MAFLD.
Symptoms that sound like acute liver failure (deep jaundice, confusion, vomiting blood) are an emergency-care question, not a preventative-testing question.
The tests
What the blood tests actually measure
A standard Australian liver panel is easy to misread as a fatty-liver test. It is not. ALT, AST and GGT answer a narrower question: are hepatocytes leaking enzymes, or is the liver being induced to make more GGT, right now?
ALT: the most liver-specific leak
Alanine transaminase sits in the cytosol of hepatocytes, where it helps move amino groups during amino-acid metabolism. It appears in blood in meaningful amounts when those cells are damaged. Australian Prescriber treats ALT above 35 U/L in women and above 40 U/L in men as raised. Your own report uses the interval your lab printed.
AST: the same job, more tissues
Aspartate aminotransferase does similar work and also leaks with cell injury, but it lives in cytosol and mitochondria, and it is also in skeletal muscle, heart, kidney and red cells. An isolated AST rise after hard training is a muscle story until creatine kinase says otherwise. As fibrosis advances, AST often rises relative to ALT, which is one reason FIB-4 puts AST in the numerator.
GGT: leak is the wrong word
Gamma-glutamyl transferase sits on bile-duct lining cells and takes part in glutathione handling. It rises with cholestasis, and separately when alcohol or some medicines induce the liver to make more of it, with no cell death required. Obesity and insulin resistance also move it. It is sensitive. It is not a fatty-liver diagnosis.
Platelets sit on the fibrosis score, not the fat score
A full blood count is not a liver test. Portal hypertension and splenic sequestration lower the platelet count as fibrosis advances, which is why Sterling et al. put platelets in the FIB-4 denominator. A normal platelet count does not mean the liver is free of fat.
Albumin and bilirubin sit on the same printout and answer a different question again: what the liver is still making and clearing. They move late. They do not image fat. For the enzyme-by-enzyme walkthrough, including ALP and Gilbert syndrome, see the liver function test guide.
For what ALT, AST and GGT actually measure, and how to read the rest of a liver panel, see the liver function test guide.
Reading your results
How to read an Australian liver printout
An Australian LFT report usually lists the same fields in a fixed order, each with its own reference interval. For a fatty-liver question, read which field is flagged before treating the panel as one score.
ALT (sometimes still printed as SGPT)
The field clinicians weight first for hepatocyte injury. A flag here is a reason to think of MAFLD, alcohol, medicines, viral hepatitis, or iron overload. It is not a fat percentage.
AST (sometimes still printed as SGOT)
Read it next to ALT. A ratio below 1, when at least one enzyme is up, leans toward metabolic or viral injury. A ratio above 2 leans toward alcohol-related injury. Advanced cirrhosis from any cause can also lift the ratio, so it is a pattern clue.
GGT
Often the first enzyme to move with regular alcohol, and also with metabolic load. Isolated GGT with a normal ALT and AST is usually not active cell death.
Platelet count, on the FBC
Needed if someone is going to calculate FIB-4. It will not be on the LFT block. Look for ×10^9/L. Age has to come from you, not from the analyser.
Units are U/L for the enzymes. Overseas IU/L is the same scale. Do not convert them the way you convert HbA1c.
Limits of ALT
Why a normal ALT does not rule it out
The result that surprises people is a normal ALT with later imaging that shows steatosis. That is not a lab error. It is what the enzyme is built to do.
Enzymes measure leak, not stored fat
ALT rises when hepatocyte membranes are disrupted now. Fat can accumulate for years with only intermittent injury. Australian Prescriber says abnormal liver tests are neither sensitive nor specific for MAFLD, and that MAFLD can be present with normal tests.
AusDiab: most FLI-defined MAFLD had a normal ALT
Farrell et al. (Scientific Reports, 2022) analysed 4,747 adults from the 2012 AusDiab survey, aged 34 to 97. They defined MAFLD as a Fatty Liver Index above 60 plus metabolic risk, not as an ultrasound. Thirty-seven percent met that definition. Only 22% of that group had ALT at or above 40 IU/L in men or 30 IU/L in women. Elevated ALT in the whole cohort was 13%.
CrossRoads II is a second FLI estimate, not a national scan
Roberts et al. (MJA, 2021) used the same Fatty Liver Index rule in 705 adults from four Goulburn Valley towns. Crude NAFLD prevalence was 38.9%. Age- and sex-standardised prevalence was 35.7%. Mean ALT in the NAFLD group was 29 U/L, only 5 U/L above the group without it. That is a regional biomarker study, not an imaged census of Australia.
Advanced fibrosis is uncommon. BARD is not the rate.
Australian Prescriber cites advanced fibrosis in 3 to 7.6% of people with MAFLD in Australia. AusDiab also reported that 61% of its MAFLD group had a BARD score suggesting risk of advanced fibrosis. The paper's own title flags that as a proportions problem: a high-sensitivity score will call risk far more often than biopsy-class advanced disease exists. This page does not treat 61% as the Australian fibrosis rate.
A normal ALT is reassuring about current leak. It is not a clearance certificate for liver fat, and it is not a fibrosis stage.
Fibrosis risk
FIB-4 is a fibrosis screen
Once MAFLD is on the table, Australian primary care is supposed to ask a second question: what is the chance of advanced fibrosis? FIB-4 is the first-line tool for that question. It is a calculator, not a draw.
The formula, and why those four inputs
Sterling et al. (Hepatology, 2006) built FIB-4 in HIV and hepatitis C coinfection: (age in years × AST in U/L) ÷ (platelet count in ×10^9/L × square root of ALT in U/L). Age stands in for time spent fibrosing. AST rises as injury reaches mitochondria and as the AST/ALT ratio climbs. Platelets fall as portal pressure rises and the spleen sequesters them. ALT is in the denominator because a higher AST/ALT pattern tracks more advanced disease.
GESA cut-offs are not the original hepatitis C cut-offs
Sterling's original pair was below 1.45 and above 3.25. For MAFLD, GESA and Australian Prescriber use below 1.3 as low risk in adults 35 to 65 (negative predictive value 95 to 97%), 1.3 to 2.7 as indeterminate, and above 2.7 as high risk and a reason to refer. About 20% of people with MAFLD land in the middle band (Adams et al., MJA 2025) and need elastography, Hepascore, or an ELF test, or a clinician who does this work.
Age bands, and when the score lies
Do not use FIB-4 under 35. Over 65, Australian Prescriber raises the low-risk cut-off to below 2.0 (McPherson et al., 2017). The score can be falsely high in thrombocytopenia from a non-liver cause, or in acute hepatitis. It does not measure fat. Ultrasound and CT are also poor at staging fibrosis, which is why the score exists.
Hemexa does not print a FIB-4
Hemexa reports ALT, AST and a platelet count, and it calculates an AST/ALT ratio. It does not compute FIB-4. A GP or an online calculator that uses your age can. Treating a Hemexa dashboard as a fibrosis stage is the version of this page that is most likely to be wrong.
A low FIB-4 is a reason to manage metabolic risk and repeat the score in one to three years, not a reason to ignore the liver. A high score is a referral prompt, not a cirrhosis diagnosis from a webpage.
Insulin resistance is an upstream driver of hepatic fat. For the earlier fasting pair, see the insulin resistance symptoms guide. For the diagnostic glucose labels, see the prediabetes blood tests guide. Raised ferritin with a normal transferrin saturation is a common metabolic pattern; see the ferritin and iron studies guide.
Who to test
Who should consider testing?
GESA recommendation 1 is the who: adults with obesity, type 2 diabetes, or two or more other metabolic risk factors should be assessed for MAFLD. Ultrasound is the first-line steatosis test in that group. Enzymes are the cheap filter that often starts the conversation.
Metabolic risk, even with a normal ALT
Type 2 diabetes, obesity, or two of hypertension, dyslipidaemia, prediabetes and related metabolic features. Australian Prescriber says prevalence is greater than 50% in type 2 diabetes, obesity, or two or more metabolic risk factors. That is who to assess, not who already has a diagnosis.
A flagged liver panel
A raised ALT, AST or GGT is a reason to think of MAFLD and also of alcohol, medicines, viral hepatitis and iron overload. GESA wants hepatitis B and C serology, and iron studies, when aminotransferases are up. A raised ferritin with transferrin saturation above 45% should prompt HFE testing, the usual Australian trigger for hereditary haemochromatosis; see the ferritin and iron studies guide for the specific thresholds.
An incidental steatotic ultrasound
Many people find out because an ultrasound was done for gallstones, pain, or something else. That image can start the MAFLD pathway. It still does not stage fibrosis, and it still does not replace a metabolic and alcohol history.
Adams et al. (Journal of Gastroenterology and Hepatology, 2020) modelled an 85% rise in incident advanced liver disease and liver-related deaths from fatty liver disease in Australia between 2019 and 2030, using the NAFLD definition current when the paper was written. That is a population forecast, not your personal timeline.
Limits
What blood tests cannot show
A useful report answers a narrow question. Here is what these tests are not doing.
Whether you have fat in the liver
ALT, AST and GGT do not image steatosis. Australian first-line diagnosis of hepatic steatosis is ultrasound. MRI is more accurate and rarely first-line. A Fatty Liver Index is a research and epidemiology tool, not a substitute for the scan GESA wants.
Whether you have MASH
Steatohepatitis is fat plus inflammation and hepatocyte injury. Blood can raise suspicion. Histology is the direct measure. No enzyme pattern on this page is a MASH diagnosis.
Your fibrosis stage, from enzymes alone
Standard liver tests are inaccurate for advanced fibrosis and can be normal in cirrhosis. FIB-4 helps rule advanced fibrosis out. Elastography or a direct serum fibrosis test sits in the middle band. Biopsy remains the reference technique and is not a screening test.
How much alcohol "caused" the picture
GGT and an AST/ALT ratio above 2 can lean toward alcohol-related injury. They cannot count drinks, and they cannot split MAFLD from MetALD for you. That split is a history plus a clinician.
Which diet or drug will clear the fat
No TGA-approved medicine is indicated specifically for MAFLD in Australia as of the April 2026 Australian Prescriber update. Published weight-loss histology data exist. They are not a protocol this page can write for you.
Deep jaundice, confusion, or vomiting blood is an emergency-care question, not a fatty-liver-guide question.
How to order
How Australians get these tests
| Approach | Best for | Typical cost | What it covers |
|---|---|---|---|
| GP-ordered Medicare liver panel | A clinical indication: flagged enzymes, metabolic risk, medicine monitoring, or symptoms | Often bulk-billed or low gap when eligible. Item 66512 covers five or more tests from item 66500. Schedule fee $17.70. | The standard LFT block: ALT, AST, GGT, ALP, bilirubin, albumin and total protein. Not ultrasound. Not FIB-4 as a named item. |
| GP-ordered liver ultrasound | Adults GESA says should be assessed for MAFLD, or a steatosis question after abnormal enzymes | Often bulk-billed or low gap when the request is clinically indicated. Fees vary by provider and region. | Hepatic steatosis as increased echogenicity. Poor at staging fibrosis. Hemexa does not perform imaging. |
| FIB-4 from existing bloods | Someone who already has MAFLD on the table and a recent AST, ALT and platelet count | Usually no extra draw if the pair already exists. Some pathology providers now report FIB-4. Online calculators are free and are not a diagnosis. | A fibrosis-risk number. Not a fat percentage. Not a Hemexa dashboard field. |
| Private or preventative liver panel | Asymptomatic testing outside an MBS indication | Standalone private LFT panels are often quoted around $25 to $80, or bundled in a wider panel. | The same enzyme block. Still not an ultrasound. |
| Membership platforms (e.g. Hemexa) | Repeating ALT, AST, GGT and the rest of the liver block on one record, next to glucose, lipids and ferritin | ~$1,199/year (full membership) | Those liver markers on the annual baseline, among 76–80 signature markers. Not FIB-4. Not ultrasound. Not a 75 g OGTT. |
Pathology in Australia requires an authorised request from a registered medical practitioner. Collection for Hemexa members is through Healius Pathology, with regional brands that differ by state. A request form is not a diagnosis, and a membership is not a substitute for a GP visit about jaundice, confusion, or a result already in a specialist range.
FAQ
Frequently asked questions
- Can a blood test diagnose fatty liver?
- No. Australian Prescriber and GESA treat liver ultrasound as the first-line test for hepatic steatosis. Blood enzymes can raise the question and can miss the condition entirely. A Fatty Liver Index is a research estimate, not the scan those documents want.
- What is the difference between MAFLD, MASLD and NAFLD?
- NAFLD was the older exclusionary name. MASLD is the 2023 international rename (steatosis plus a cardiometabolic risk factor, with excess alcohol handled separately as MetALD). MAFLD is the name Australian colleges still use, and it can sit beside another cause such as alcohol. For most people the clinical picture is the same. The letterhead is not.
- Can I have fatty liver if my ALT is normal?
- Yes. In Farrell et al. 2022, only 22% of AusDiab adults who met a Fatty Liver Index definition of MAFLD had a raised ALT. Enzymes measure current leak, not stored fat.
- What is FIB-4, and do I need it?
- FIB-4 is (age × AST) ÷ (platelets × √ALT). GESA uses it after MAFLD is identified, to help rule out advanced fibrosis. Below 1.3 is low risk in adults 35 to 65. It is not a fat test, it should not be used under 35, and Hemexa does not calculate it.
- Do I need to fast for these tests?
- A liver function test does not require fasting. If the same form includes fasting glucose, insulin, or a lipid profile, you fast for the visit. Ultrasound preparation is a separate instruction from the imaging provider.
- Does Medicare cover fatty liver blood tests?
- A GP-ordered liver panel can be funded under MBS item 66512 when there is a clinical indication (schedule fee $17.70 for five or more tests from item 66500). There is no dedicated "fatty liver" item. Ultrasound funding depends on the clinical request. Preventative panels without an indication are often private.
- How much do fatty liver blood tests cost in Australia?
- A clinically indicated GP liver panel is commonly bulk-billed. Private standalone panels are often $25 to $80. Memberships that include the liver block on a panel of 76–80 signature markers start around AU$1,199 per year. Imaging and second-line fibrosis tests are priced separately.
- Is fatty liver reversible?
- Fat in the liver can fall when the metabolic drivers change. Published histology series link greater weight loss with greater improvement. That is not a protocol, a timeline, or a promise this page can make for you. Talk to your GP about the metabolic work, not about a search-result stack.
- Does Hemexa test for fatty liver?
- Hemexa includes ALT, AST, GGT, ALP, albumin, bilirubin and a platelet count on the annual baseline, among 76–80 signature markers, and it calculates an AST/ALT ratio. Collection is through Healius Pathology. Hemexa does not calculate FIB-4, does not perform ultrasound, and does not diagnose MAFLD. A membership does not replace a GP visit for jaundice or a specialist-range result.
How Hemexa fits
How Hemexa can help
A high ALT with a metabolic history, or a normal ALT that still does not settle the question, is common. The useful product move is to put the liver enzymes next to glucose, lipids, ferritin and platelets on one record, then read the trend, rather than treating each PDF as a one-off scare.
Liver enzymes once a year, not on the six-month retest
Hemexa includes ALT, AST, GGT, ALP, albumin, total bilirubin, globulin and total protein on the 76–80 marker annual baseline, under Liver Function. Platelets sit on the full blood count. Those liver enzymes run annually because they are used as a filter, not as a weekly score.
AST/ALT is calculated. FIB-4 is not.
Hemexa calculates the AST/ALT ratio on every panel. It does not calculate FIB-4. The inputs exist. The score is a clinical tool for a GP after MAFLD is identified, not a Hemexa product claim.
Dashboard bands are Hemexa policy
Live Hemexa range-policy rows treat ALT at or below 25 U/L as the preventative optimal band, with a watch ceiling at the Healius Pathology reference floor (36 U/L in women, 41 U/L in men). AST and GGT follow the same pattern. Those bands sit inside the lab interval. They are company clinical policy, not a GESA diagnostic threshold, and a result inside them does not rule out steatosis.
Clinical safety review on a marked rise
An ALT or AST above 200 U/L is flagged in Hemexa's clinical safety review for same-day follow-up. That is a damage-marker threshold, not a fatty-liver stage. Hemexa does not run ultrasound or elastography.
Collection through Healius Pathology
Healius Pathology is Hemexa's collection partner, with regional brands that differ by state. Results from other Australian labs can be imported after your first baseline.
Sources
References
O'Halloran, R., Adams, L. A., Deed, G., and Lubel, J. S. (2026). Metabolic dysfunction-associated fatty liver disease: an update. Australian Prescriber, 49, 44-49. View source ↗
Adams, L. A., Kemp, W. W., Muller, K. R., et al. (2025). Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary. Medical Journal of Australia, 223(5), 268-276. View source ↗
MAFLD Consensus Statement Working Group. (2024). Recommendations for the assessment of metabolic dysfunction-associated fatty liver disease (MAFLD) in primary care: a consensus statement. Gastroenterological Society of Australia. View source ↗
Rinella, M. E., et al. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology, 79(6), 1542-1556. View source ↗
Farrell, A. M., Magliano, D. J., Shaw, J. E., et al. (2022). A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study. Scientific Reports, 12, 1956. View source ↗